The Portuguese universal access program to direct-acting antivirals (Sovaldi® and Harvoni®) for the treatment of Hepatitis C : a financial analysis of the first 2 years
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Tipo de documento: | Dissertação |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.14/22681 |
Resumo: | Nowadays, 350.000 people die annually due to the direct or indirect action of the Hepatitis C virus, responsible for many acute and chronic hepatitis worldwide and their further progression to more severe diseases like Hepatic Cirrhosis and Hepatocellular Carcinoma. Portugal is no exception as 150.000 people are estimated to be infected with related deaths up to 1.200 annually. Two years ago, after Gilead's development of two new drugs - Sovaldi® (Sofosbuvir) and Harvoni® (Sofosbuvir + Ledipasvir) - with treatment success rates around 95%, the Portuguese government took the decision of granting universal access to this drugs to all patients infected with the HCV, regardless of the stage of progression of the disease. The objective of this thesis is therefore to perform an economic analysis of this measure, understanding the impact, costs and benefits for the patients and healthcare system, what conclusions are willing to be taken and how can it influence future deals. The collection of data from the Infarmed press releases as well as previous studies enabled the comparison of the economic profit for the government when treating patients with Sovaldi® / Harvoni® versus Pegylated Interferon and Ribavirin. The results showed that the new therapy is cost-effective, increasing HCV infected patients’ life expectancy while avoiding many severe occurrences. |
id |
RCAP_b1bd65dc73c15b235e281072d149c6f2 |
---|---|
oai_identifier_str |
oai:repositorio.ucp.pt:10400.14/22681 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
The Portuguese universal access program to direct-acting antivirals (Sovaldi® and Harvoni®) for the treatment of Hepatitis C : a financial analysis of the first 2 yearsHepatitis CSovaldiHarvoniSofosbuvirLedipasvirMarkov ModelHepatite CModelo de MarkovDomínio/Área Científica::Ciências Sociais::Economia e GestãoNowadays, 350.000 people die annually due to the direct or indirect action of the Hepatitis C virus, responsible for many acute and chronic hepatitis worldwide and their further progression to more severe diseases like Hepatic Cirrhosis and Hepatocellular Carcinoma. Portugal is no exception as 150.000 people are estimated to be infected with related deaths up to 1.200 annually. Two years ago, after Gilead's development of two new drugs - Sovaldi® (Sofosbuvir) and Harvoni® (Sofosbuvir + Ledipasvir) - with treatment success rates around 95%, the Portuguese government took the decision of granting universal access to this drugs to all patients infected with the HCV, regardless of the stage of progression of the disease. The objective of this thesis is therefore to perform an economic analysis of this measure, understanding the impact, costs and benefits for the patients and healthcare system, what conclusions are willing to be taken and how can it influence future deals. The collection of data from the Infarmed press releases as well as previous studies enabled the comparison of the economic profit for the government when treating patients with Sovaldi® / Harvoni® versus Pegylated Interferon and Ribavirin. The results showed that the new therapy is cost-effective, increasing HCV infected patients’ life expectancy while avoiding many severe occurrences.Actualmente, 350.000 pessoas morrem anualmente devido à acção directa ou indirecta do vírus da Hepatite C. Portugal não é excepção, uma vez que se estima que 150.000 pessoas estejam infectadas e que ocorram anualmente 1.200 mortes relacionadas com este vírus. Há dois anos atrás, após o desenvolvimento por parte da Gilead de dois novos fármacos – Sovaldi® (Sofosbuvir) e Harvoni® (Sofosbuvir + Ledipasvir) – com taxas de sucesso de tratamento à volta dos 95%, o governo português tomou a decisão de garantir o acesso universal destes fármacos a todos os pacientes infectados com o VHC, independentemente do estádio de progressão da doença. Esta tese pretende realizar uma análise económica desta medida, tentando calcular o impacto, os custos e os benefícios que pode trazer para os pacientes e para o Sistema Nacional de Saúde, tendo a noção que as conclusões obtidas poderão influenciar decisões futuras. Os dados recolhidos do Infarmed conjugados com o de estudos anteriores permitiram comparar os ganhos económicos para o Estado ao tratar pacientes com Sovaldi® / Harvoni® quando comparado com Interferão Peguilado e Ribavirina. No final, os resultados mostraram que a nova terapia é custo-efectiva, aumentando a esperança média de vida dos pacientes infectados com VHC e permitindo evitar um grande número de ocorrências graves.Pinheiro, Susana Frazão Ferreira FernandesVeritati - Repositório Institucional da Universidade Católica PortuguesaEsteves, Bernardo Augusto Pessoa de Amorim da Costa2017-07-31T09:48:44Z2017-07-1320172017-07-13T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://hdl.handle.net/10400.14/22681TID:201725274enginfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-12T17:28:54Zoai:repositorio.ucp.pt:10400.14/22681Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T18:18:48.879425Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
The Portuguese universal access program to direct-acting antivirals (Sovaldi® and Harvoni®) for the treatment of Hepatitis C : a financial analysis of the first 2 years |
title |
The Portuguese universal access program to direct-acting antivirals (Sovaldi® and Harvoni®) for the treatment of Hepatitis C : a financial analysis of the first 2 years |
spellingShingle |
The Portuguese universal access program to direct-acting antivirals (Sovaldi® and Harvoni®) for the treatment of Hepatitis C : a financial analysis of the first 2 years Esteves, Bernardo Augusto Pessoa de Amorim da Costa Hepatitis C Sovaldi Harvoni Sofosbuvir Ledipasvir Markov Model Hepatite C Modelo de Markov Domínio/Área Científica::Ciências Sociais::Economia e Gestão |
title_short |
The Portuguese universal access program to direct-acting antivirals (Sovaldi® and Harvoni®) for the treatment of Hepatitis C : a financial analysis of the first 2 years |
title_full |
The Portuguese universal access program to direct-acting antivirals (Sovaldi® and Harvoni®) for the treatment of Hepatitis C : a financial analysis of the first 2 years |
title_fullStr |
The Portuguese universal access program to direct-acting antivirals (Sovaldi® and Harvoni®) for the treatment of Hepatitis C : a financial analysis of the first 2 years |
title_full_unstemmed |
The Portuguese universal access program to direct-acting antivirals (Sovaldi® and Harvoni®) for the treatment of Hepatitis C : a financial analysis of the first 2 years |
title_sort |
The Portuguese universal access program to direct-acting antivirals (Sovaldi® and Harvoni®) for the treatment of Hepatitis C : a financial analysis of the first 2 years |
author |
Esteves, Bernardo Augusto Pessoa de Amorim da Costa |
author_facet |
Esteves, Bernardo Augusto Pessoa de Amorim da Costa |
author_role |
author |
dc.contributor.none.fl_str_mv |
Pinheiro, Susana Frazão Ferreira Fernandes Veritati - Repositório Institucional da Universidade Católica Portuguesa |
dc.contributor.author.fl_str_mv |
Esteves, Bernardo Augusto Pessoa de Amorim da Costa |
dc.subject.por.fl_str_mv |
Hepatitis C Sovaldi Harvoni Sofosbuvir Ledipasvir Markov Model Hepatite C Modelo de Markov Domínio/Área Científica::Ciências Sociais::Economia e Gestão |
topic |
Hepatitis C Sovaldi Harvoni Sofosbuvir Ledipasvir Markov Model Hepatite C Modelo de Markov Domínio/Área Científica::Ciências Sociais::Economia e Gestão |
description |
Nowadays, 350.000 people die annually due to the direct or indirect action of the Hepatitis C virus, responsible for many acute and chronic hepatitis worldwide and their further progression to more severe diseases like Hepatic Cirrhosis and Hepatocellular Carcinoma. Portugal is no exception as 150.000 people are estimated to be infected with related deaths up to 1.200 annually. Two years ago, after Gilead's development of two new drugs - Sovaldi® (Sofosbuvir) and Harvoni® (Sofosbuvir + Ledipasvir) - with treatment success rates around 95%, the Portuguese government took the decision of granting universal access to this drugs to all patients infected with the HCV, regardless of the stage of progression of the disease. The objective of this thesis is therefore to perform an economic analysis of this measure, understanding the impact, costs and benefits for the patients and healthcare system, what conclusions are willing to be taken and how can it influence future deals. The collection of data from the Infarmed press releases as well as previous studies enabled the comparison of the economic profit for the government when treating patients with Sovaldi® / Harvoni® versus Pegylated Interferon and Ribavirin. The results showed that the new therapy is cost-effective, increasing HCV infected patients’ life expectancy while avoiding many severe occurrences. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-07-31T09:48:44Z 2017-07-13 2017 2017-07-13T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.14/22681 TID:201725274 |
url |
http://hdl.handle.net/10400.14/22681 |
identifier_str_mv |
TID:201725274 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799131880900001792 |